FDA warns of dosing errors with compounded injectable semaglutide In July 2024, the FDA warned that patient inexperience with measuring and self-administering injectable compound semaglutide products has led to five to 20 times more than the intended dose of semaglutide
Those with multiple baseline risk factors, such as age greater than 60 and on chronic methylprednisolone, are at even higher risk of these serious side effects if a quinolone antibiotic is also prescribed
Comparing GLP-1 Therapies: Semaglutide, Ozempic, Wegovy, and Mounjaro at Vive Ageless Weight Loss Center Compounded semaglutide is a custom-made version of the drug, prepared by compounding pharmacies without FDA approval, while Ozempic, Wegovy, and Mounjaro are FDA-approved medications for managing diabetes and obesity
Lipid & Cardiovascular Profile Important for heart health risk